US › Healthcare

Pasithea Therapeutics Corp (KTTA)

US · Healthcare · Biotechnology

$0.46+3.00%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.9M
Profit YoY
+19.5%
EPS
$-0.12
EPS estimate
$-0.45

EPS came in at -0.12 against a street estimate of -0.45 — a beat of 73.3%.

Key statistics

Market cap
$15.4M
Forward P/E
0.0
P/B
0.28
Book value
$2.20
EPS (TTM)
$-1.42
52-week high
$2.06
52-week low
$0.28
50-day MA
$0.55
200-day MA
$0.77
Beta
0.29

Analyst view

Analysts rate Pasithea Therapeutics Corp a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $3.00.

Shareholding

Insiders
1.11%
Institutions
64.06%

Largest institutional holders

FundStake
Vivo Capital, LLC6.28%
HHG PLC6.28%
Squadron Capital Management LLC6.28%
Adage Capital Partners Gp LLC6.28%
Ameriprise Financial Inc4.04%
Cable Car Capital LLC3.61%
Stonepine Capital Management Llc2.49%
AdvisorShares Investments, LLC1.01%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Pasithea Therapeutics Corp — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.